Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).
Identifieur interne : 000689 ( Main/Exploration ); précédent : 000688; suivant : 000690Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).
Auteurs : Shiona K. Glass [Canada] ; David L. Pearl ; Scott A. Mcewen ; Rita FinleySource :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2010.
Descripteurs français
- KwdFr :
- Antibactériens (usage thérapeutique), Azithromycine (usage thérapeutique), Canada (épidémiologie), Clarithromycine (usage thérapeutique), Connaissances, attitudes et pratiques en santé (MeSH), Facteurs de risque (MeSH), Facteurs socioéconomiques (MeSH), Grippe humaine (épidémiologie), Humains (MeSH), Macrolides (usage thérapeutique), Saisons (MeSH), Utilisation médicament (statistiques et données numériques), Érythromycine (usage thérapeutique).
- MESH :
- statistiques et données numériques : Utilisation médicament.
- usage thérapeutique : Antibactériens, Azithromycine, Clarithromycine, Macrolides, Érythromycine.
- épidémiologie : Canada, Grippe humaine.
- Connaissances, attitudes et pratiques en santé, Facteurs de risque, Facteurs socioéconomiques, Humains, Saisons.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (therapeutic use), Azithromycin (therapeutic use), Canada (epidemiology), Clarithromycin (therapeutic use), Drug Utilization (statistics & numerical data), Erythromycin (therapeutic use), Health Knowledge, Attitudes, Practice (MeSH), Humans (MeSH), Influenza, Human (epidemiology), Macrolides (therapeutic use), Risk Factors (MeSH), Seasons (MeSH), Socioeconomic Factors (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Azithromycin, Clarithromycin, Erythromycin, Macrolides.
- geographic , epidemiology : Canada.
- epidemiology : Influenza, Human.
- statistics & numerical data : Drug Utilization.
- Health Knowledge, Attitudes, Practice, Humans, Risk Factors, Seasons, Socioeconomic Factors.
Abstract
OBJECTIVES
To assess provincial-level predictors among socioeconomic and influenza rate data for the use of different macrolide antimicrobials in Canada from 2000 to 2006.
METHODS
Multivariable models were developed to describe macrolide defined daily doses per capita.
RESULTS
Use was highest during October to March for all macrolides. Investigated yearly and provincial patterns differed considerably among the macrolide agents. Associations with socioeconomic variables were similar between clarithromycin and erythromycin, while azithromycin consumption showed some differences in its association with these variables. Consistently, the rate of influenza was significantly associated with increased macrolide use. The influenza rate interacted with socioeconomic variables in some models; as the influenza rate increased, the greatest increase in demand for macrolides occurred in populations with high percentages of low-income individuals, high unemployment levels and low percentages of individuals with bachelor's degrees.
CONCLUSIONS
The impact of associations among macrolide consumption, influenza and socioeconomic factors may reflect inappropriate use of these agents to treat viral infections and/or prescribing for secondary infections, and knowledge of the virus versus bacteria problem and accessibility of healthcare. Further research surrounding differences in access to antimicrobial prescriptions and treatment options between advantaged and disadvantaged populations is suggested to further understand the dynamics of antimicrobial use in Canada.
DOI: 10.1093/jac/dkp391
PubMed: 19864333
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).</title><author><name sortKey="Glass, Shiona K" sort="Glass, Shiona K" uniqKey="Glass S" first="Shiona K" last="Glass">Shiona K. Glass</name><affiliation wicri:level="1"><nlm:affiliation>Department of Population Medicine, University of Guelph, Ontario, Canada. sglass@uoguelph.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Population Medicine, University of Guelph, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Pearl, David L" sort="Pearl, David L" uniqKey="Pearl D" first="David L" last="Pearl">David L. Pearl</name></author><author><name sortKey="Mcewen, Scott A" sort="Mcewen, Scott A" uniqKey="Mcewen S" first="Scott A" last="Mcewen">Scott A. Mcewen</name></author><author><name sortKey="Finley, Rita" sort="Finley, Rita" uniqKey="Finley R" first="Rita" last="Finley">Rita Finley</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:19864333</idno><idno type="pmid">19864333</idno><idno type="doi">10.1093/jac/dkp391</idno><idno type="wicri:Area/Main/Corpus">000733</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000733</idno><idno type="wicri:Area/Main/Curation">000733</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000733</idno><idno type="wicri:Area/Main/Exploration">000733</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).</title><author><name sortKey="Glass, Shiona K" sort="Glass, Shiona K" uniqKey="Glass S" first="Shiona K" last="Glass">Shiona K. Glass</name><affiliation wicri:level="1"><nlm:affiliation>Department of Population Medicine, University of Guelph, Ontario, Canada. sglass@uoguelph.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Population Medicine, University of Guelph, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Pearl, David L" sort="Pearl, David L" uniqKey="Pearl D" first="David L" last="Pearl">David L. Pearl</name></author><author><name sortKey="Mcewen, Scott A" sort="Mcewen, Scott A" uniqKey="Mcewen S" first="Scott A" last="Mcewen">Scott A. Mcewen</name></author><author><name sortKey="Finley, Rita" sort="Finley, Rita" uniqKey="Finley R" first="Rita" last="Finley">Rita Finley</name></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Canada (epidemiology)</term><term>Clarithromycin (therapeutic use)</term><term>Drug Utilization (statistics & numerical data)</term><term>Erythromycin (therapeutic use)</term><term>Health Knowledge, Attitudes, Practice (MeSH)</term><term>Humans (MeSH)</term><term>Influenza, Human (epidemiology)</term><term>Macrolides (therapeutic use)</term><term>Risk Factors (MeSH)</term><term>Seasons (MeSH)</term><term>Socioeconomic Factors (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antibactériens (usage thérapeutique)</term><term>Azithromycine (usage thérapeutique)</term><term>Canada (épidémiologie)</term><term>Clarithromycine (usage thérapeutique)</term><term>Connaissances, attitudes et pratiques en santé (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Facteurs socioéconomiques (MeSH)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Macrolides (usage thérapeutique)</term><term>Saisons (MeSH)</term><term>Utilisation médicament (statistiques et données numériques)</term><term>Érythromycine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Azithromycin</term><term>Clarithromycin</term><term>Erythromycin</term><term>Macrolides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Utilization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Utilisation médicament</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Azithromycine</term><term>Clarithromycine</term><term>Macrolides</term><term>Érythromycine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Health Knowledge, Attitudes, Practice</term><term>Humans</term><term>Risk Factors</term><term>Seasons</term><term>Socioeconomic Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Connaissances, attitudes et pratiques en santé</term><term>Facteurs de risque</term><term>Facteurs socioéconomiques</term><term>Humains</term><term>Saisons</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To assess provincial-level predictors among socioeconomic and influenza rate data for the use of different macrolide antimicrobials in Canada from 2000 to 2006.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Multivariable models were developed to describe macrolide defined daily doses per capita.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Use was highest during October to March for all macrolides. Investigated yearly and provincial patterns differed considerably among the macrolide agents. Associations with socioeconomic variables were similar between clarithromycin and erythromycin, while azithromycin consumption showed some differences in its association with these variables. Consistently, the rate of influenza was significantly associated with increased macrolide use. The influenza rate interacted with socioeconomic variables in some models; as the influenza rate increased, the greatest increase in demand for macrolides occurred in populations with high percentages of low-income individuals, high unemployment levels and low percentages of individuals with bachelor's degrees.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The impact of associations among macrolide consumption, influenza and socioeconomic factors may reflect inappropriate use of these agents to treat viral infections and/or prescribing for secondary infections, and knowledge of the virus versus bacteria problem and accessibility of healthcare. Further research surrounding differences in access to antimicrobial prescriptions and treatment options between advantaged and disadvantaged populations is suggested to further understand the dynamics of antimicrobial use in Canada.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19864333</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation></Journal><ArticleTitle>Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).</ArticleTitle><Pagination><MedlinePgn>148-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkp391</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess provincial-level predictors among socioeconomic and influenza rate data for the use of different macrolide antimicrobials in Canada from 2000 to 2006.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multivariable models were developed to describe macrolide defined daily doses per capita.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Use was highest during October to March for all macrolides. Investigated yearly and provincial patterns differed considerably among the macrolide agents. Associations with socioeconomic variables were similar between clarithromycin and erythromycin, while azithromycin consumption showed some differences in its association with these variables. Consistently, the rate of influenza was significantly associated with increased macrolide use. The influenza rate interacted with socioeconomic variables in some models; as the influenza rate increased, the greatest increase in demand for macrolides occurred in populations with high percentages of low-income individuals, high unemployment levels and low percentages of individuals with bachelor's degrees.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The impact of associations among macrolide consumption, influenza and socioeconomic factors may reflect inappropriate use of these agents to treat viral infections and/or prescribing for secondary infections, and knowledge of the virus versus bacteria problem and accessibility of healthcare. Further research surrounding differences in access to antimicrobial prescriptions and treatment options between advantaged and disadvantaged populations is suggested to further understand the dynamics of antimicrobial use in Canada.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Shiona K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, University of Guelph, Ontario, Canada. sglass@uoguelph.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearl</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>McEwen</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Finley</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018942">Macrolides</NameOfSubstance></Chemical><Chemical><RegistryNumber>63937KV33D</RegistryNumber><NameOfSubstance UI="D004917">Erythromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>H1250JIK0A</RegistryNumber><NameOfSubstance UI="D017291">Clarithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017291" MajorTopicYN="N">Clarithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004917" MajorTopicYN="N">Erythromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19864333</ArticleId><ArticleId IdType="pii">dkp391</ArticleId><ArticleId IdType="doi">10.1093/jac/dkp391</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Finley, Rita" sort="Finley, Rita" uniqKey="Finley R" first="Rita" last="Finley">Rita Finley</name><name sortKey="Mcewen, Scott A" sort="Mcewen, Scott A" uniqKey="Mcewen S" first="Scott A" last="Mcewen">Scott A. Mcewen</name><name sortKey="Pearl, David L" sort="Pearl, David L" uniqKey="Pearl D" first="David L" last="Pearl">David L. Pearl</name></noCountry><country name="Canada"><noRegion><name sortKey="Glass, Shiona K" sort="Glass, Shiona K" uniqKey="Glass S" first="Shiona K" last="Glass">Shiona K. Glass</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000689 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000689 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19864333
|texte= Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19864333" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |